@Article{Pertyński2004,
journal="Menopause Review/Przegląd Menopauzalny",
issn="1643-8876",
volume="3",
number="3",
year="2004",
title="Transdermal applying of 17\β-oestradiol. Is this a progress in hormone replacement therapy?",
abstract="The group of 1790 women (51.92\±4.52 years), having commenced transdermal HRT \– matrix patches with 17\β-oestradiol (Oesclim, Laboratoires Fournier), entered this study. The observational period \– three months of HRT. The following parameters were under evaluation: 1) climacteric symptoms intensity; 2) side-effects estimation (breast pain, allergic reactions, changes in body weight and arterial hypertension); 3) patch detachment frequency; 4) patien\’t will for continuation of hormonal therapy and 5) general efficacy of the treatment. Obtained results: 1) Transdermal oestradiol in the form of matrix patch is effective and safe in the therapy of climacteric symptoms in menopausal women; 2) Breast pain and a slight body mass gain are typical \”start\” symptoms for HRT, being present in less than half of patients; 3) Matrix patches are characterized by good skin adherence and low percentage of local and general allergic reactions; 4) Positive assessment of the therapy made by our patients resulted in high and increasing percentage of women willing to continue this type of transdermal HRT.",
author="Pertyński, Tomasz
and Stachowiak, Grzegorz",
pages="41--48",
url="https://www.termedia.pl/Transdermal-applying-of-17-946-oestradiol-Is-this-a-progress-in-hormone-replacement-therapy-,4,2409,1,1.html"
}